Close Menu

NCCN

A study questioned the cost-effectiveness of the test in clinically low-risk women, but the firm stressed that a wealth of evidence continues to support its use under current guidelines.

Invitae and Tulane University researchers found 37 percent of patients with positive germline results were not covered by testing guidelines in place at the time.

Missed a Few

Newsday reports that breast cancer genetic testing guidelines for are out of date and may miss individuals.

The new additions reflect data published this summer in the TAILORx trial, which speak to the chemopredictive ability of Genomic Health's Oncotype DX.

The company highlighted growth in demand for its test , and is now ramping up marketing and focusing on its IVD development plans.

The American Cancer Society today lowered the recommended age for screening patients at average risk for the disease to 45 from 50 years old.

The updated recommendations discuss testing for DNA repair gene mutations, MSI-H, and dMMR, as well as germline testing and counseling.

The company touted the recent spate of positive payor coverage decisions it has seen for its ConfirmMDx and SelectMDx prostate cancer tests.

The network said MDxHealth's ConfirmMDx should be used to screen men at higher risk for prostate cancer despite a negative biopsy. 

NEW YORK (GenomeWeb) – The National Comprehensive Cancer Network has included two molecular diagnostics – Myriad Genetics' Prolaris and Genomic Health's Oncotype DX Prostate Cancer – in its most recent guidelines for the disease, noting that these two assays "appear further along in development a

Pages

A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.

The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.

Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.

In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.